Noviscend Announces New distribution Agreement with Myriad Genetics

Noviscend Inc, a Canadian medical technology company announced today an agreement with Myriad Genetics, Inc., a leader in genetic testing and precision medicine, for the distribution of its portfolio of genetic tests.  Effective immediately, under this new agreement, Noviscend becomes the exclusive distributor of EndoPredict®, MyRisk®, myChoiceCDx®, GeneSight®, Prolaris®, and myRisk® - Hereditary and Single Gene Panel molecular diagnostic tests in Canada.

“For almost 10 years, Myriad Genetics has been active in Canada, making these diagnostic tests accessible to oncologists, gynecologists and pathologists, supporting them in making crucial treatment decisions for their patients”, said Kostas Trakas, CEO at Noviscend Inc. “At Noviscend we look forward to continuing this legacy of service to our customers, but we will also endeavour to expand the diagnostic solutions available for Canadian patients.”

Noviscend would also like to welcome Mark Hammar as Head, Diagnostic Products and Services for Noviscend Inc.  As the former country leader for Myriad Genetics Canada, Mark will be a critical leader during this transition period and beyond.

Accelera Medtech Canada is Now Noviscend!

What’s in a name? Over the past year, we’ve come to realize that our business is quickly evolving. Our focus has always been on delivering healthcare system solutions and when we founded Accelera Medtech Canada, we specifically wanted to bring innovative medical devices to the Canadian market. However, one of the things we’ve learned in speaking with potential partners over 2020 was that devices were only part of the solution for the challenges facing healthcare.

While this seems like a significant change, our core beliefs haven’t changed. Over the last few months, we have thought long and hard about creating a new name that would convey who we are, and what we seek to accomplish. In the spirit of rebranding, we will continue to commit to our customers and partners that we provide the same high level of professionalism you have experienced, and we’d like to take the opportunity to thank our loyal customers and business partners for your trust and friendship in our business.

As Noviscend expands its product portfolio in Canada, we will continue to focus our business development activities on branded prescription products and medical devices that are in late-stage development, or currently approved and commercialized outside Canada, or approved in Canada but falling outside the license holder’s business focus. Our therapeutic categories of interest for proprietary products will continue to include neurology, psychiatry, dermatology, pain management, and women's health - although we may consider other opportunities outside of these areas if there is a strategic rationale.

As you notice changes in our branding, we would certainly appreciate hearing from you. If you use social media, please connect with us that way. And as always, feel free to reach out with any thoughts or questions any time.

CEO, Kostas Trakas stated “As part of our focus on delivering innovative healthcare solutions, our leadership team and I believe it was appropriate to rebrand our company and are very excited about the introduction of our new company name, Noviscend Inc., because it allows us to better represent our aspirations to both our consumers and partners.”

About Noviscend Inc.
Headquartered in Mississauga, Ontario, Canada, Noviscend Inc.’s mission is to acquire and commercialize innovative devices and pharmaceuticals in targeted therapeutic areas with high unmet needs in Canada.

For more information regarding this announcement, please contact:
Noviscend Inc.
Kostas Trakas
Chief Executive Officer
+1-289-497-9447
ktrakas@noviscend.com

Acquisition of Iris Technologies

Accelera Medtech Canada Enters into the Post-Concussion Management Market with the Acquisition of Iris Technologies


The Iris Monitor, finds a new home with Ontario-based Accelera Medtech Canada

BURLINGTON, Ontario - Oct. 8, 2019 - PRLog -- Accelera Medtech Canada is pleased to announce the acquisition of Iris Technologies and its flagship product - the Iris Monitor - the world's first computer monitors clinically proven to help concussion patients reduce the painful symptoms of light sensitivity when using a computer.

"Our acquisition of Iris Technologies is in line with our vision to bring innovative medical technologies to the Canadian and, through partnerships, global markets. This investment represents an important strategic opportunity to build a portfolio of medical and consumer healthcare offerings that we believe will improve the health and well-being of patients living with traumatic brain injuries such as concussions," said Kostas Trakas, CEO of Accelera Medtech Canada.

Iris Technologies is a Canadian assistive technology start-up founded in 2015 by two Queen's University graduates, Colin Harding and Conor Ross, seeking to offer concussion patients a faster road back to work and the classroom. "Colin and I are incredibly excited about the opportunity this affords Iris. Our biggest priority has always been to get the Iris Monitor in the hands of those who need it most and Accelera Medtech allows the company to do this in a substantial way. We could not have got to this point without the help of our families, investors, The Canadian Concussion Centre, Queens Innovation Connector, and The Ryerson Biomedical Zone."

With one in five Canadians affected by a sport-related concussion injury(1) and 1.5 million currently living with a brain injury(2), there is a significant financial burden borne by patients, businesses and insurers due to the inability of many concussion patients to return to work or school.

More information about the Iris Monitor can be found here:

Kostas Trakas

CEO, Noviscend Inc.


  1. http://nationalpost.com/sports/one-in-five-canadians-have-suffered-concussions-playing-sports-angus-reid-i nstitute-poll-says

  2. http://braininjurycanada.ca/wp-content/uploads/2007/05/BIAC-Fact-Sheet-2014.pdf

Canadian Tech Start-Up Speeds Post-Concussion Return to Work and School

The Iris Monitor is clinically proven to enable concussion patients to use computers without the painful symptoms caused by exposure to LCD screens

TORONTO, ON – April 11, 2018 –Iris Technologies, a Canadian assistive technology start-up founded by two Queen’s University graduates, is offering concussion patients a faster road back to work and the classroom. With the launch of their flagship product - The Iris Monitor - they offer the world’s first computer monitor clinically proven to help concussion patients reduce the painful symptoms of light sensitivity when using a computer.
Co-founders Conor Ross and Colin Harding are passionate about making a difference in the lives of concussion patients. “When my brother suffered a concussion two years ago, painful light sensitivity kept him out of school and away from his friends for a long-time, which made him feel isolated. Ever since then, we have been committed to developing assistive technologies to help concussion patients regain control of their lives and reconnect with society,” said Conor.


The Iris Monitor features a unique 13.3” e-paper screen, which uses magnetized polymer to create shapes on the display, as opposed to the light modulating liquid crystals of a typical LCD computer screen. By adapting current monitor technology, The Iris Monitor features a screen that is not constantly refreshing and is not backlit. For post-concussion syndrome sufferers, symptoms triggered by light and motion are significantly reduced. This allows users to reintroduce daily computer tasks and increase their level of productivity.


With an overwhelming one in five Canadians affected by sport-related concussion injury (see ref 1) and 1.5 million currently living with a brain injury (see ref 2), the inability of many concussion patients to return to work is costing patients, businesses and insurers significant financial losses.

“My most painful concussion symptom to date has been severe sensitivity to light, which made using my computer next to impossible,” said David Goldband, Vice President at Grant Thornton, a Toronto-based accounting firm. “Not only has The Iris Monitor allowed me to use my computer again and get back to work much sooner, it helped me reconnect with my friends and family online.”

In a recent clinical trial, The Iris Monitor enabled concussion patients to use their computers longer, with a significant reduction in the often painful symptoms caused by the light sensitivity typically triggered by liquid crystal display (LCD) screens (see ref 3).

“Computer screen intolerance due to light sensitivity occurs in up to 43 per cent of individuals facing ongoing symptoms after a concussion. In severe cases, painful symptoms such as photophobia and light sensitivity can last several years or even permanently,” said Dr. Charles Tator, neurosurgeon and Director of the Canadian Concussion Centre at Toronto Western Hospital who led the clinical study of the Iris Monitor. “Clinical study participants who used the monitor reported fewer exacerbated symptoms, an increased ability to focus, and that the screen was easier on the eyes.” Iris Technologies is already seeing positive interest and demand for The Iris Monitor. Pilot programs testing the device are already underway at top-tier educational institutions and other large organizations including the University of Toronto, Appleby College, Ivy League schools, an insurance company, the Government of Ontario and a selection of human resources departments and occupational therapy clinics.

About Iris Technologies:

Iris Technologies is an assistive technology start-up founded in 2015 by Queen’s University graduates, Conor Ross and Colin Harding, focused on shortening the journey from a concussion back to a normal life. Iris Technologies now works out of the Biomedical Zone, a physician led healthcare technology incubator.



1. http://nationalpost.com/sports/one-in-five-canadians-have-suffered-concussions-playing-sports-angus-reidinstitute-poll-says

2. http://braininjurycanada.ca/wp-content/uploads/2007/05/BIAC-Fact-Sheet-2014.pdf

3. http://www.uhn.ca/corporate/News/PressReleases/Pages/NonLCD_technology_shows_promise_for_return_to_work_school_for_postconcussion_syndrome_sufferers.aspx